Format

Send to

Choose Destination
Front Immunol. 2018 Jun 7;9:1252. doi: 10.3389/fimmu.2018.01252. eCollection 2018.

The Notch Signaling Pathway Is Balancing Type 1 Innate Lymphoid Cell Immune Functions.

Perchet T1,2,3, Petit M1,2,3, Banchi EG1,2,3, Meunier S1,2,3, Cumano A1,2,3, Golub R1,2,3.

Author information

1
Unit for Lymphopoiesis, Department of Immunology, Pasteur Institute, Paris, France.
2
INSERM U1223, Paris, France.
3
Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France.

Abstract

The Notch pathway is one of the canonical signaling pathways implicated in the development of various solid tumors. During carcinogenesis, the Notch pathway dysregulation induces tumor expression of Notch receptor ligands participating to escape the immune surveillance. The Notch pathway conditions both the development and the functional regulation of lymphoid subsets. Its importance on T cell subset polarization has been documented contrary to its action on innate lymphoid cells (ILC). We aim to analyze the effect of the Notch pathway on type 1 ILC polarization and functions after disruption of the RBPJk-dependent Notch signaling cascade. Indeed, type 1 ILC comprises conventional NK (cNK) cells and type 1 helper innate lymphoid cells (ILC1) that share Notch-related functional characteristics such as the IFNg secretion downstream of T-bet expression. cNK cells have strong antitumor properties. However, data are controversial concerning ILC1 functions during carcinogenesis with models showing antitumoral capacities and others reporting ILC1 inability to control tumor growth. Using various mouse models of Notch signaling pathway depletion, we analyze the effects of its absence on type 1 ILC differentiation and cytotoxic functions. We also provide clues into its role in the maintenance of immune homeostasis in tissues. We show that modulating the Notch pathway is not only acting on tumor-specific T cell activity but also on ILC immune subset functions. Hence, our study uncovers the intrinsic Notch signaling pathway in ILC1/cNK populations and their response in case of abnormal Notch ligand expression. This study help evaluating the possible side effects mediated by immune cells different from T cells, in case of multivalent forms of the Notch receptor ligand delta 1 treatments. In definitive, it should help determining the best novel combination of therapeutic strategies in case of solid tumors.

KEYWORDS:

Notch; cancer; cytotoxicity; inflammation; innate lymphoid cells; liver; molecular biology techniques; transcription factors

PMID:
29930552
PMCID:
PMC5999736
DOI:
10.3389/fimmu.2018.01252
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center